These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 34418400)

  • 41. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).
    Owens TD; Smith PF; Redfern A; Xing Y; Shu J; Karr DE; Hartmann S; Francesco MR; Langrish CL; Nunn PA; Gourlay SG
    Clin Transl Sci; 2022 Feb; 15(2):442-450. PubMed ID: 34724345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
    Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
    Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
    N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
    Koch JC; Leha A; Bidner H; Cordts I; Dorst J; Günther R; Zeller D; Braun N; Metelmann M; Corcia P; De La Cruz E; Weydt P; Meyer T; Großkreutz J; Soriani MH; Attarian S; Weishaupt JH; Weyen U; Kuttler J; Zurek G; Rogers ML; Feneberg E; Deschauer M; Neuwirth C; Wuu J; Ludolph AC; Schmidt J; Remane Y; Camu W; Friede T; Benatar M; Weber M; Lingor P;
    Lancet Neurol; 2024 Nov; 23(11):1133-1146. PubMed ID: 39424560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.